News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. to Present Preclinical Data at the 2013 American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Molecular Targets and Cancer Therapeutics


10/15/2013 9:38:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present preclinical research on two novel potential cancer therapies, MM-398 and MM-141, and an innovative platform for biomarker analysis at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place on October 19-23, 2013 at the Hynes Convention Center in Boston, Massachusetts. Presentations will include preclinical studies of MM-398, a nanolipsomal encapsulated form of irinotecan, and MM-141, a bispecific antibody co-targeting IGF-1R and ErbB3, and their activity in tumor models. Data will be shared in three poster sessions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES